Stoke Therapeutics, Inc. (STOK) — closed signal from February 5, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on May 6, 2026.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published February 5, 2026
Stoke is a stock where the recent trend and news matter more than finding a bargain. Company updates clarified when a big trial will progress and a new HQ lease signals plans to sell products later. The stock has not fallen a lot, so the plan is to buy small dips while demand for biotech is positive. Trade small because the stock can swing widely and trades lightly.
Primary drivers
- Clearer late-stage trial timing focuses attention on milestones
- New headquarters lease points to building a sales organization
- Current upward trend makes buying dips preferable to chasing gains
- Positive biotech sentiment could amplify moves in coming months
How it played out
STOK: target stayed out of reach
Lyra published STOK on February 5, 2026 at $33.27, with expected growth of 22%. The thesis pointed to clearer late-stage trial timing, a new headquarters lease, the current upward trend, and positive biotech sentiment as possible supports. It also said the stock could swing widely and traded lightly.
Inside the window, STOK rose to $40.22 on March 10, 2026, a 20.9% peak gain. That stayed below the $40.59 target, so the target was never reached. The stock ended the window at $33.28. The thesis mostly played out on direction and momentum, but it missed the published target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.